Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27233233 | 0.85 | TDP1 (0.69) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL27233227 | 0.85 | TDP1 (0.69) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL29928558 | 0.80 | TDP1 (0.75) | TDP1FOLH1CAPN1 | |
| SCHEMBL9807479 | 0.77 | TDP1 (0.77) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL18025616 | 0.76 | FOLH1 (0.52) | TDP1FOLH1CAPN1PLGPRSS1 | |
| SCHEMBL12809811 | 0.76 | TDP1 (0.73) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL10044328 | 0.75 | TDP1 (0.72) | TDP1FOLH1CAPN1PLGPRSS1 | |
| SCHEMBL29744917 | 0.73 | TDP1 (0.62) | TDP1FOLH1CAPN1CNR1 | |
| SCHEMBL29869498 | 0.73 | FOLH1 (0.57) | TDP1FOLH1CAPN1PLGPRSS1 | |
| SCHEMBL10308270 | 0.72 | TDP1 (0.74) | TDP1FOLH1CAPN1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130818-B2 | Transglutamine tag for efficient site-specific bioconjugation | MERCK PATENT GMBH (DE) | 2021-09-28 | — | — | US | disclosed |
| US-20190194344-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | MERCK PATENT GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130818-B2 | Transglutamine tag for efficient site-specific bioconjugation | TGM2, FOLH1, BPGM | TDP1 2013/4885FOLH1 2/4885CAPN1 4712/4885 |
| US-20190194344-A1 | A TRANSGLUTAMINE TAG FOR EFFICIENT SITE-SPECIFIC BIOCONJUGATION | TGM2, BPGM, FOLH1 | TDP1 2029/4885FOLH1 3/4885CAPN1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.